fda pulling semaglutide alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products FDA Approves Game-Changing Weight Loss

Discontinue Wegovy in patients at least 2 months before a planned pregnancy Pediatric: Adverse reactions with Wegovy in pediatric patients aged 12 years with obesity were similar to those reported in adults in weight reduction trials

It remains unapproved for human use at time of writing (April 2026)

Hormonal changes drive weight gain, bone loss, and higher risk for costly conditions like obesity and type 2 diabetes

Oral glutathione carries even lower risk due to limited absorption

At Passion Health Advanced Primary Care, patients can get personalized guidance for weight management, diabetes care, nutrition concerns, and medication monitoring

Missing a dose carries the risk of lost therapeutic benefit, potential dose reset, and the frustration of losing momentum